全文获取类型
收费全文 | 126270篇 |
免费 | 9989篇 |
国内免费 | 3476篇 |
专业分类
耳鼻咽喉 | 991篇 |
儿科学 | 2288篇 |
妇产科学 | 1806篇 |
基础医学 | 6947篇 |
口腔科学 | 2882篇 |
临床医学 | 15299篇 |
内科学 | 18493篇 |
皮肤病学 | 2334篇 |
神经病学 | 6410篇 |
特种医学 | 4038篇 |
外国民族医学 | 39篇 |
外科学 | 12321篇 |
综合类 | 19121篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5793篇 |
眼科学 | 2033篇 |
药学 | 10392篇 |
85篇 | |
中国医学 | 11139篇 |
肿瘤学 | 17299篇 |
出版年
2024年 | 108篇 |
2023年 | 2229篇 |
2022年 | 3216篇 |
2021年 | 5254篇 |
2020年 | 5316篇 |
2019年 | 4751篇 |
2018年 | 4527篇 |
2017年 | 4993篇 |
2016年 | 5289篇 |
2015年 | 5052篇 |
2014年 | 9373篇 |
2013年 | 11650篇 |
2012年 | 7666篇 |
2011年 | 8082篇 |
2010年 | 6630篇 |
2009年 | 6046篇 |
2008年 | 5892篇 |
2007年 | 6321篇 |
2006年 | 5641篇 |
2005年 | 5012篇 |
2004年 | 4048篇 |
2003年 | 3664篇 |
2002年 | 3011篇 |
2001年 | 2667篇 |
2000年 | 2188篇 |
1999年 | 1699篇 |
1998年 | 1328篇 |
1997年 | 1109篇 |
1996年 | 900篇 |
1995年 | 899篇 |
1994年 | 708篇 |
1993年 | 538篇 |
1992年 | 483篇 |
1991年 | 445篇 |
1990年 | 375篇 |
1989年 | 328篇 |
1988年 | 319篇 |
1987年 | 276篇 |
1986年 | 216篇 |
1985年 | 258篇 |
1984年 | 227篇 |
1983年 | 167篇 |
1982年 | 167篇 |
1981年 | 166篇 |
1980年 | 129篇 |
1979年 | 123篇 |
1978年 | 65篇 |
1977年 | 44篇 |
1976年 | 49篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
992.
993.
Nittaya Phanuphak Nipat Teeratakulpisarn Frits van Griensven Nitiya Chomchey Suteeraporn Pinyakorn James LK Fletcher Rapee Trichavaroj Supanit Pattanachaiwit Nelson Michael Praphan Phanuphak Jerome H Kim Jintanat Ananworanich 《Journal of the International AIDS Society》2015,18(1)
Introduction
HIV transmission risk is highest during acute HIV infection (AHI). We evaluated HIV RNA in the anogenital compartment in men who have sex with men (MSM) during AHI and compared time to undetectable HIV RNA after three-drug versus five-drug antiretroviral therapy (ART) to understand risk for onward HIV transmission.Methods
MSM with AHI (n=54) had blood, seminal plasma and anal lavage collected for HIV RNA at baseline, days 3 and 7, and weeks 2, 4, 12 and 24. Data were compared between AHI stages: 1 (fourth-generation antigen-antibody combo immunoassay [IA]–, third-generation IA–, n=15), 2 (fourth-generation IA+, third-generation IA–, n=9) and 3 (fourth-generation IA+, third-generation IA+, western blot–/indeterminate, n=30) by randomization to five-drug (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18) versus three-drug (tenofovir+emtricitabine+efavirenz, n=18) regimens.Results
Mean age was 29 years and mean duration since HIV exposure was 15.4 days. Mean baseline HIV RNA was 5.5 in blood, 3.9 in seminal plasma and 2.6 log10 copies/ml in anal lavage (p<0.001). Blood and seminal plasma HIV RNA were higher in AHI Stage 3 compared to Stage 1 (p<0.01). Median time from ART initiation to HIV RNA <50 copies/ml was 60 days in blood, 15 days in seminal plasma and three days in anal lavage. Compared with the three-drug ART, the five-drug ART had a shorter time to HIV RNA <1500 copies/ml in blood (15 vs. 29 days, p=0.005) and <50 copies/ml in seminal plasma (13 vs. 24 days, p=0.048).Conclusions
Among MSM with AHI, HIV RNA was highest in blood, followed by seminal plasma and anal lavage. ART rapidly reduced HIV RNA in all compartments, with regimen intensified by raltegravir and maraviroc showing faster HIV RNA reductions in blood and seminal plasma. 相似文献994.
995.
Julia L Finkelstein Pooja Gala Rosemary Rochford Marshall J Glesby Saurabh Mehta 《Journal of the International AIDS Society》2015,18(1)
Introduction
Lipodystrophy is a term used to describe a metabolic complication of fat loss, fat gain, or a combination of fat loss and gain, which is associated with some antiretroviral (ARV) therapies given to HIV-infected individuals. There is limited research on lipodystrophy in low- and middle-income countries, despite accounting for more than 95% of the burden of HIV/AIDS. The objective of this review was to evaluate the prevalence, pathogenesis and prognosis of HIV-related lipoatrophy, lipohypertrophy and mixed syndrome, to inform clinical management in resource-limited settings.Methods
We conducted a structured literature search using MEDLINE electronic databases. Relevant MeSH terms were used to identify published human studies on HIV and lipoatrophy, lipohypertrophy, or mixed syndrome in low-, low-middle- and upper-middle-income countries through 31 March 2014. The search resulted in 5296 articles; after 1599 studies were excluded (958 reviews, 641 non-human), 3697 studies were extracted for further review. After excluding studies conducted in high-income settings (n=2808), and studies that did not meet inclusion criteria (n=799), 90 studies were included in this review.Results and Discussion
Of the 90 studies included in this review, only six were from low-income countries and eight were from lower middle-income economies. These studies focused on lipodystrophy prevalence, risk factors and side effects of antiretroviral therapy (ART). In most studies, lipodystrophy developed after the first six months of therapy, particularly with the use of stavudine. Lipodystrophy is associated with increased risk of cardiometabolic complications. This is disconcerting and anticipated to increase, given the rapid scale-up of ART worldwide, the increasing number and lifespan of HIV-infected patients on long-term therapy, and the emergence of obesity and non-communicable diseases in settings with extensive HIV burden.Conclusions
Lipodystrophy is common in resource-limited settings, and has considerable implications for risk of metabolic diseases, quality of life and adherence. Comprehensive evidence-based interventions are urgently needed to reduce the burden of HIV and lipodystrophy, and inform clinical management in resource-limited settings. 相似文献996.
997.
Management of interstitial cystitis/bladder pain syndrome (IC/BPS) remains a challenge due to poor understanding on its etiology. Complementary and alternative medicine (CAM), as an optional treatment, has been widely used, because no definitive conventional therapy is available. The different domain of CAM provides miscellaneous treatments for IC/BPS, which mainly include dietary modification, nutraceuticals, bladder training, biofeedback, yoga, massage, physical therapy, Qigong, traditional Chinese medicine and acupuncture. Clinical evidence has shown that each therapy can certainly benefit a portion of IC/BPS patients. However, the target patient group of each therapy has not been well studied and randomized, controlled trials are needed to further confirm the efficacy and reliability of CAM on managing IC/BPS. Despite these limitations, CAM therapeutic characteristics including non-invasive and effectiveness for specific patients allow clinicians and patients to realize multimodal and individualized therapy for IC/BPS. 相似文献
998.
Mauro Cervigni 《Translational andrology and urology》2015,4(6):638-642
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease characterized by discomfort or recurrent abdominal and pelvic pains in the absence of urinary tract infections. Its symptomatology includes discomfort, increased bladder pressure, sensitivity and intense pain in the bladder and pelvic areas, increased voiding frequency and urgency, or a combination of these symptoms. For these reasons, this pathology has a very negative impact on quality of life. The etiology of IC/BPS is still not well understood and different hypotheses have been formulated, including autoimmune processes, allergic reactions, chronic bacterial infections, exposure to toxins or dietary elements, and psychosomatic factors. The finding of an effective and specific therapy for IC/BPS remains a challenge for the scientific community because of the lack of a consensus regarding the causes and the inherent difficulties in the diagnosis. The last recent hypothesis is that IC/BPS could be pathophysiologically related to a disruption of the bladder mucosa surface layer with consequent loss of glycosaminoglycans (GAGs). This class of mucopolysaccharides has hydrorepellent properties and their alteration expose the urothelium to many urinary toxic agents. It has been hypothesized that when these substances penetrate the bladder wall a chain is triggered in the submucosa. In order to improve the integrity and function of the bladder lining, GAG layer replenishment therapy is widely accepted as therapy for patients with IC/BPS who have poor or inadequate response to conventional therapy. Currently, Chondroitin sulfate (CS), heparin, hyaluronic acid (HA), and pentosan polysulphate (PPS), and combinations of two GAGs (CS and HA) are the available substances with different effectiveness rates in patients with IC/BPS. There are four different commercially available products for GAG replenishment including CS, heparin, HA and PPS. Each product has different concentrations and dosage formulations. Recently, a combination of CS and HA is the latest commercially available product with promising results. 相似文献
999.
1000.